Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Following several years of development and validation, we applied the WOMAC Osteoarthritis Index as the principal outcome measure in a double blind randomized parallel trial of Meclomen (100 mg po tid) and Voltaren (25 mg po tid). Statistically significant improvements in clinical status were noted in both treatment groups. At the doses studied, between drug differences favoring Meclomen were observed in pain and stiffness, no difference being noted in physical function. No significant between drug difference was noted in tolerability at these same doses. Our study also demonstrated that the relative efficiency of WOMAC was similar to that of the Lequesne and Doyle indices. Finally, we defined the standard deviation necessary to calculate sample size for future studies using the WOMAC index, both for studies based on static scores and those based on change scores.
 ...
PMID:Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. 155 79

Meclofenamate sodium, a nonsteroidal anti-inflammatory agent, was compared at two dose levels (100 mg and 200 mg) with codeine (60 mg) and placebo in a double-blind, randomized study of 218 women after normal vaginal delivery. The purpose was to determine the analgesic efficacy and safety of meclofenamate sodium for the short-term treatment of acute episiotomy pain. Meclofenamate sodium was significantly better than placebo in most measures of pain relief and reduction of pain intensity. The 100-mg dose of meclofenamate sodium was significantly better than codeine in relieving pain. Adverse experiences with the study medications were minimal (6.4%). Patients receiving codeine reported more side effects than did those receiving either dose of meclofenamate sodium. Meclofenamate sodium is a safe, effective analgesic for acute episiotomy pain.
 ...
PMID:Double-blind comparison of meclofenamate sodium with codeine and placebo for the pain of episiotomy. 332 76

Meclofenamate sodium, a nonsteroidal anti-inflammatory drug with proven analgesic effects, was compared at two dose levels (200 mg and 100 mg) with codeine (60 mg) and placebo in a double-blind, randomized study of 327 women experiencing episiotomy pain after normal delivery. Meclofenamate sodium at either dose was significantly better than codeine or placebo in reducing pain intensity and increasing pain relief, and it had a longer duration of action. Adverse effects were minimal, and their frequency did not differ significantly among treatment groups. Meclofenamate sodium appears to be as safe as and more effective than codeine for the management of episiotomy pain.
 ...
PMID:Comparison of meclofenamate sodium with codeine and placebo for the treatment of episiotomy pain. 332 77

The analgesic effect of meclofenamate sodium at two dose levels (100 mg and 200 mg) was compared with the effects of buffered aspirin (600 mg) and placebo in a double-blind, randomized study of 105 dental outpatients with acute pain following third-molar extraction. Meclofenamate sodium at either dose level was significantly superior to both buffered aspirin and placebo, resulting in significantly greater relief of pain. All four treatments were well tolerated, and side effects were minimal. Meclofenamate sodium is a safe, highly effective analgesic for the relief of acute pain.
 ...
PMID:Comparison of meclofenamate sodium with buffered aspirin and placebo for the relief of postoperative dental pain. 332 78

Meclofenamate sodium was compared, double-blind, with codeine and placebo for the treatment of acute episiotomy pain. One hundred sixty-eight women with moderate or severe episiotomy pain after normal delivery were assigned randomly to one of four treatment groups: one received meclofenamate sodium 200 mg at dose 1 and 100 mg at doses 2 and 3; one received meclofenamate sodium 100 mg at dose 1 and 50 mg at doses 2 and 3; one received codeine 60 mg at all three doses; and one received placebo at all three doses. Efficacy measurements were evaluated periodically for 6 hours after medication. After the first administration, both doses of meclofenamate sodium were significantly superior to placebo and to codeine from 2-6 hours in pain intensity difference and pain relief. For second and third doses, data were available for too few patients to allow valid analysis and interpretation. Adverse effects occurred in 4 patients in each meclofenamate sodium group, and in 8 in the codeine group and in 6 in the placebo group. The study indicates that single 100- and 200-mg doses of meclofenamate sodium are as safe as, and significantly more effective than, codeine 60 mg or placebo for episiotomy pain.
 ...
PMID:Analgesic efficacy of meclofenamate sodium in episiotomy pain. 354 Aug 70

The efficacy of meclofenamate sodium (Meclomen) at two different doses was compared with that of buffered aspirin and placebo in the control of postsurgical pain in a double-blind, randomized study of 205 patients. Meclofenamate sodium, 200 mg, was significantly better than meclofenamate sodium, 100 mg, in some efficacy parameters. Both doses of meclofenamate sodium were superior to buffered aspirin in most parameters of efficacy, and more effective than placebo in every parameter.
 ...
PMID:Comparison of meclofenamate sodium with buffered aspirin and placebo in the treatment of postsurgical dental pain. 385 95

The analgesic effectiveness of meclofenamate sodium (Meclomen) at two dose levels, 200 mg and 100 mg, was compared with the effectiveness of a placebo and aspirin, 600 mg, in a double-blind study of 174 adult outpatients who had undergone removal of impacted third molars. When compared with the placebo, meclofenamate sodium at either dose level produced a significantly greater reduction in pain intensity, greater pain relief, fewer withdrawals for inefficacy, greater percentage of patients who considered their medication effective, and greater percentage of patients considered by the investigator to have received drug-attributable benefits. In comparison with aspirin, 600 mg, meclofenamate sodium at either 200 mg or 100 mg produced significantly greater reduction in pain intensity and greater pain relief. The other measures of efficacy showed no significant differences between the two drugs. Side effects were minimal in all treatment groups. Meclofenamate sodium appears to be a safe and effective analgesic for the control of pain.
 ...
PMID:Control of pain with meclofenamate sodium following removal of an impacted molar. 389 6

20 patients with an attack of acute gout participated in this double-blind study, ten patients received N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) and ten indometacin. The median time interval between onset of attack and onset of treatment was 11 h in the meclofenamate sodium group and 14 h in the indometacin group; medication was started with a dose of 200 mg meclofenamate sodium or 25 mg indometacin followed by 100 mg meclofenamate sodium or 25 mg indometacin every 4 h for the first 24 h. Thereafter patients received 100 mg meclofenamate sodium or 50 mg indometacin at 8-h intervals for 6 days. Similar improvement of intensity of spontaneous pain, swelling, tenderness of touch and degree of limitation of function was noted in patients of both treatment groups. This improvement could already be noted after 24 h of treatment and was sustained throughout the medication period and follow-up period. Adverse reactions were reported by 2 patients in the meclofenamate sodium group and by 5 patients in the indometacin group. The results of this double-blind study indicate that meclofenamate sodium in the dose administered was equally effective in relieving pain and inflammation and restoring restricted function in patients with acute gout as indometacin when used in the generally recommended dose for this indication. Meclofenamate sodium, even at these high dosage levels, was better tolerated than indometacin.
 ...
PMID:Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. 634 48

N-(2,6-Dichloro-m-tolyl) anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) was compared to placebo in two controlled multicenter trials of similar design, one in 180 patients with osteoarthritis of the hip and the other in 237 patients with osteoarthritis of the knee. Following one week on placebo to establish a baseline, patients were given meclofenamate sodium (300 mg/day) or placebo for a four-week double-blind controlled period of treatment. Improvement with meclofenamate sodium consistently exceeded that with placebo. In the hip and knee trials, the differences were statistically significant for at least three of the four weekly visits in reduction of pain on walking, pain on starting motion, pain on passive motion, night pain (knee only), and tenderness. Early in the study, statistically significant improvement was also observed in tenderness measures of the knee and fabere measures of hip function. At each weekly observation, significantly better global assessment scores of patient condition were reported by the patients (p less than 0.005) and their physicians (p less than 0.01) in the group receiving meclofenamate sodium in both the hip and knee trials. Overall global improvement was reported in 76% of the patients on drug and 42% of those on placebo. 31% of the patients receiving meclofenamate sodium and 23% receiving placebo reported adverse reactions. Gastrointestinal reactions were more frequent among the patients receiving the drug. The improvement achieved during the double-blind phase was maintained or increased in 359 patients who continued into long-term therapy with meclofenamate sodium. Meclofenamate sodium was judged effective and safe in the treatment of osteoarthritis of the hip and knee.
 ...
PMID:Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience. 634 49

161 patients with extra-articular or non-articular disorders as acute shoulder syndrome, periarthritis humero scapularis, syndrome of the angular of the scapula, acute olecranon bursitis, acute epicondylitis and/or epitrochleitis or periarthritis of the hip were treated in this double-blind multicenter study. 53 patients received 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for a maximum of 3 weeks, 54 received 150 mg indomethacin per day and 54 received placebo. Meclofenamate sodium was significantly superior to placebo in the treatment of such symptoms as spontaneous pain, pain on motion, tenderness on pressure associated with acute episodes of extra- or non-articular rheumatism as demonstrated by earlier and superior improvement. Indomethacin showed comparable efficacy. Adverse reactions, mostly gastrointestinal symptoms, were reported by 15 patients receiving meclofenamate sodium (28.3%), 26 patients taking indomethacin (48.2%) and 5 patients in the placebo group (9.3%). The tolerance of meclofenamate sodium was good with the distinct clinical impression that meclofenamate sodium was better tolerated than indomethacin.
 ...
PMID:Double-blind multicenter study comparing meclofenamate sodium with indomethacin and placebo in the treatment of extra-articular rheumatic disease. 634 50


1 2 Next >>